» Articles » PMID: 36082113

Coronary Functional Assessment in Non-obstructive Coronary Artery Disease: Present Situation and Future Direction

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Non-obstructive coronary artery disease (CAD), which is defined as coronary stenosis <50%, has been increasingly recognized as an emerging entity in clinical practice. Vasomotion abnormality and coronary microvascular dysfunction are two major mechanisms contributing to the occur of angina with non-obstructive CAD. Although routine coronary functional assessment is limited due to several disadvantages, functional evaluation can help to understand the pathophysiological mechanism and/or to exclude specific etiologies. In this review, we summarized the potential mechanisms involved in ischemia with non-obstructive coronary arteries (INOCA) and myocardial infarction with non-obstructive coronary arteries (MINOCA), the two major form of non-obstructive CAD. Additionally, we reviewed currently available functional assessment indices and their use in non-obstructive CAD. Furthermore, we speculated that novel technique combined anatomic and physiologic parameters might provide more individualized therapeutic choice for patients with non-obstructive CAD.

Citing Articles

Beyond the Obstructive Paradigm: Unveiling the Complex Landscape of Nonobstructive Coronary Artery Disease.

Tudurachi A, Anghel L, Tudurachi B, Zavoi A, Ceasovschih A, Sascau R J Clin Med. 2024; 13(16).

PMID: 39200755 PMC: 11354865. DOI: 10.3390/jcm13164613.


Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link?.

Stangret A, Sadowski K, Jablonski K, Kochman J, Opolski G, Grabowski M Int J Mol Sci. 2024; 25(7).

PMID: 38612695 PMC: 11012077. DOI: 10.3390/ijms25073885.


Diffuse non-obstructive coronary artery disease: two clinical faces of the same disease-a case report.

Klemenc M, Budihna G, Kranjec I Eur Heart J Case Rep. 2024; 8(1):ytad605.

PMID: 38173781 PMC: 10762887. DOI: 10.1093/ehjcr/ytad605.


Pathophysiology and Outcomes of Endothelium Function in Coronary Microvascular Diseases: A Systematic Review of Randomized Controlled Trials and Multicenter Study.

Avtaar Singh S, Nappi F Biomedicines. 2022; 10(12).

PMID: 36551766 PMC: 9775403. DOI: 10.3390/biomedicines10123010.

References
1.
Sucato V, Novo G, Saladino A, Evola S, Galassi A . Coronary microvascular dysfunction. Minerva Cardioangiol. 2020; 68(2):153-163. DOI: 10.23736/S0026-4725.20.05070-7. View

2.
Tonino P, De Bruyne B, Pijls N, Siebert U, Ikeno F, van t Veer M . Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360(3):213-24. DOI: 10.1056/NEJMoa0807611. View

3.
Beltrame J, Crea F, Kaski J, Ogawa H, Ong P, Sechtem U . International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2015; 38(33):2565-2568. DOI: 10.1093/eurheartj/ehv351. View

4.
Gassenmaier S, Tsiflikas I, Greulich S, Kuebler J, Hagen F, Nikolaou K . Prevalence of pathological FFR values without coronary artery stenosis in an asymptomatic marathon runner cohort. Eur Radiol. 2021; 31(12):8975-8982. PMC: 8589749. DOI: 10.1007/s00330-021-08027-0. View

5.
Prasad A, Zareh M, Doherty R, Gopal A, Vora H, Somma K . Use of regadenoson for measurement of fractional flow reserve. Catheter Cardiovasc Interv. 2013; 83(3):369-74. DOI: 10.1002/ccd.25055. View